Results 111 to 120 of about 7,553 (206)

Bruton's tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy. [PDF]

Ann Med Surg (Lond)
Hujjat SFZ, Chandani HK, Khan MS, Chandani DK, Mahmoud A.   +4 more
europepmc   +1 more source

The BMX Tyrosine Kinase : A Signal Mediator in Hematopoietic and Endothelial/Epithelial Cells [PDF]

, 2003
Ekman, Niklas
core  

Expression of Bruton's Tyrosine Kinase Reflects Immune Cells Infiltration and Cell Proliferation in Breast Cancer. [PDF]

World J Oncol
AlRammah T, Wu R, Chida K, Kawashima K, Hakamada K, Ishikawa T, Ebos JML, Takabe K.   +7 more
europepmc   +1 more source

Inhibition of Bruton's tyrosine kinase restricts neuroinflammation following intracerebral hemorrhage. [PDF]

Theranostics
Hao H, Yin T, Li T, Zhou X, Ren H, Liu M, Huang H, Qi C, Xiu Y, Qiu W, Wang D, Shi M, Wang X, Dumont AS, Liu Q.   +14 more
europepmc   +1 more source

Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors - systematic review and meta-analysis of randomized controlled trials. [PDF]

Ann Hematol
Buchrits S, Trieman G, Giladi O, Hofstetter L, Gurion R, Granot G, Shacham-Abulafia A, Raanani P, Gafter-Gvili A.   +8 more
europepmc   +1 more source

Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies. [PDF]

Sci Rep, 2023
Alrouji M, Benjamin LS, Alhumaydhi FA, Al Abdulmonem W, Baeesa SS, Rehan M, Shahwan M, Shamsi A, Akhtar A.   +8 more
europepmc   +1 more source

Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy. [PDF]

Front Oncol
Oura M, Toho M, Ikeda D, Fukuda N, Torres AS, Fujii F, Sakuma H, Uehara A, Tabata R, Narita K, Takeuchi M, Matsue K.   +11 more
europepmc   +1 more source

UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies. [PDF]

J Hematol Oncol
Dell'Aversana C, Sgueglia G, Massaro C, Perricone U, Sarno F, Megchelenbrink WL, Conte M, Carafa V, Campanella A, Frenquelli M, Bordini J, Ghia P, Petrizzi VB, Alvarez R, Nappi D, Chiurazzi F, Tambaro FP, Wierda WG, de Lera AR, Altucci L.   +19 more
europepmc   +1 more source

A Novel Dual Bruton's Tyrosine Kinase/Janus Kinase 3 Inhibitor Wj1113 and its Therapeutic Effects on Rheumatoid Arthritis. [PDF]

MedComm (2020)
Zhang C, Lai F, Gong H, Li S, Xiang N, Que L, Xue N, Hao M, Zhou E, Wang X, Liang T, Jin J.   +11 more
europepmc   +1 more source

A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. [PDF]

Front Immunol
Qu H, Jia Y, Liu Z, Li Z, Zhao X, Wu Z, Fan G, Lou Y.   +7 more
europepmc   +1 more source